Active, Not Recruiting
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
NCT04802876
- Conditions
- Adenocarcinoma, Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, +111 more
- Locations
-
- Grupo SOLTI Barcelona, Spain